Drugs that contain Tafamidis Meglumine
1. List of Vyndaqel drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8168663 | FOLDRX PHARMS | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
Dec, 2023
(6 months from now) | |
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Apr, 2024
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2023
(6 months from now) | |
| US8653119 | FOLDRX PHARMS | Methods for treating transthyretin amyloid diseases |
Jan, 2024
(7 months from now) | |
Do you want to check out VYNDAQEL patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 3, 2024 |
| Orphan Drug Exclusivity (ODE) | May 3, 2026 |
NCE-1 date: 2023-05-04
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
More Information on Dosage
VYNDAQEL family patents
9
United States
3
Spain
3
Japan
3
European Union
2
Canada
2
Germany
2
China
2
Australia
2
Denmark
2
Portugal
2
Austria
1
Cyprus
1
Slovenia
1
Brazil
1
Luxembourg
1
South Africa
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic